Niromed - Company finances
|
EUR
|
2022
From: 2022-02-14
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 384,072 | 2,264,337 | 4,946,096 | 13,586,340 |
| Profit before tax | - | - | 691,472 | 801,247 |
| Net profit | 83,200 | 192,538 | 585,891 | 658,817 |
| Equity | 85,700 | 237,061 | 650,953 | 1,062,711 |
| Liabilities | 56,651 | 147,959 | 280,611 | 1,681,772 |
| Non-current assets | 1,271 | 2,456 | 3,621 | 16,994 |
| Current assets | 141,080 | 382,357 | 927,903 | 2,727,192 |
| Total assets | 142,351 | 384,813 | 931,524 | 2,744,186 |
|
Taxes paid
|
||||
| STI taxes | - | 136,252 | 386,748 | 383,080 |
| Social insurance contributions | - | 9,500 | 47,988 | 67,033 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +489.6% | +118.4% | +174.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 58.4% | 50.0% | 62.9% | 24.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 97.1% | 81.2% | 90.0% | 62.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 21.7% | 8.5% | 11.8% | 4.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 14.0% | 5.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 0.6 | 0.4 | 1.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 384,072 | 734,388 | 927,399 | 2,037,941 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Niromed - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-02-22 | 4943.36 |
| 2024-02-19 | 2024-02-21 | 997.76 |
| 2023-08-17 | 2023-08-30 | 0.11 |
| 2023-07-18 | 2023-07-30 | 0.11 |
| 2023-06-16 | 2023-06-29 | 0.12 |
| 2023-05-16 | 2023-05-30 | 0.12 |
| 2023-05-02 | 2023-05-14 | 0.12 |
| 2023-04-26 | 2023-04-28 | 0.12 |
| 2023-02-17 | 2023-02-20 | 772.41 |
Niromed - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-09-23 | 2025-09-25 | 2.03 |
| 2025-07-30 | 2025-07-31 | 21.6 |
| 2025-07-28 | 2025-07-29 | 21.56 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Niromed, UAB (code 306012165) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, revenue reached €13.59M, up 174.7% year on year, following growth from €2.26M in 2023 to €4.95M in 2024. Net profit also increased over the period, from €192.5K in 2023 to €585.9K in 2024 and €658.8K in 2025. However, profitability narrowed in 2025, with a profit margin of 4.8% compared with 11.8% in 2024. The balance sheet expanded materially: total assets rose to €2.74M in 2025, supported by equity of €1.06M and liabilities of €1.68M. Key ratios point to efficient use of assets, with ROE at 62.0%, ROA at 24.0%, debt-to-equity at 1.58, and asset turnover at 4.95x. Revenue per employee was €2.26M, and profit per employee €109.8K, indicating high productivity in 2025.